References
- The International non-Hodgkin's Lymphoma Prognostic Factors Project (1993). A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329, 987–994.
- Shipp, M. A., Neuberg, D., Janicek, M., Canellos, G. P. and Shulman, L. N. (1995). High-dose CHOP as initial therapy for patients with poor prognosis aggressive non-Hodgkin's lymphoma. A. dose finding study. Journal of Clinical Oncology, 13, 2916–2923.
- Avilés, A., Guzm´n, R., Delgado, S., Nambo, M. J., García, E. L. and Díaz-Maqueo, J. C. (1996). Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improved the prognosis in aggressive malignant lymphoma. American Journal of Hematology, 52, 275–280.
- Verdock, L. F., van Putten, W. L. J., Hagenbeek, A., Schouten, H. C., Sonneveld, P., van Imhoff, G., Kluin-Nelemann, H., Raemaekens, J. M. M., can Oers, R. H. J., Haak, I. H. L., Schotts, R., Dekker, A. W., Degast, G. C. and Lowenberg, B. (1995). Comparison of CHOP chemotherapy with autologous or with bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 332, 1045–1052.
- Gordon, L. I., Andersen, J., Haberman, T. M., Winter, J. N., Gillick, J., Schilder, R. J. and Cassileth, P. (1996). Phase I trial of dose escalation with growth factors support in patients with previously untreated diffuse aggressive lymphomas. Determination. of the maximun tolerated dose of Promace-CYTABomp. Journal of Clinical Oncology, 14, 1275–1281.
- Haouin, C., Lepage, E. and Gisselbrecht, C. (1994). Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate and high-grade non-Hodgkins lymphoma in first remission. A. study of 464 patients. Journal of Clinical Oncology, 12, 2543–2548.
- Gianni, A. M., Bregni, M., Siena, S., Brambila, C., Nicola, M. D., Lombardi, F., Gandula, L., Tarella, C., Pileri, A., Ramagnani, F., Valagusa, P. and Bonadona, G. (1997). High-dose chemotherapy with autologous bone marrow transplantation compared to MACOP-B in aggressive B-cell lymphoma. New England Journal of Medicine, 332, 1290–1297.
- Marteli, M., Vignetti, M., Zinzani, P. L., Gherlizani, F., Melani, G., Frachini, M., DeSanctis, V., Papa, G., Marteli, M. F., Calabresi, F., Tura, S. and Mandeli, F. (1996). High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to frontline chemotherapy. A. prospective randomised Italian Multicentric study. Journal of Clinical Oncology, 14, 134–142.
- Vitolo, V., Cortellazo, S., Liberati, A. M., Freilone, R., Falda, M., Bertini, M., Batti, B., Linieri, S., Levis, A., Locateli, F., Lawsone, E., Marmont, F., Pizzuti, M., Rossi, A., Viero, P., Barbui, T., Grignani, F. and Resegatti, L. (1997). Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem cell transplantation support as first line therapy in high-risk large cell lymphoma. Journal of Clinical Oncology, 15, 491–498.
- Avilés, A., Calva, A., Díaz-Maqueo, J. C., Talavera, A., Huerta-Guzmán and Vásquez, E. (1997). Escalation of epirubicin in the CEOP-Bleo regimen. A. controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma. Leukemia and Lymphoma, 25, 319–325.
- Avilés, A., Delgado, S., Nambo, M. J., Alatriste, S. and Díaz-Maqueo, J. C. (1994). Adjuvant radiotherapy to sites of previous bulky disease in patients with stage IV diffuse large cell lymphoma. International Journal of Radiation Oncology and Biological Physical, 30, 799–804.
- Kaplan, E. L. and Meier, P. (1958). Non parametric estimation from incomplete observations. Journal American of Statistical Association, 53, 457–481.